Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lilly Japan, Mitsubishi Tanabe Link Up to Copromote Diabetes Med Tirzepatide
July 8, 2022
- Meiji Pharma/KM Biologics Eager to Acquire mRNA Vaccine, Mull Collabs with Upstarts and Academia
July 7, 2022
- KD-414 Presumed to Have Superior Efficacy over Vaxzevria: KM Bio President
July 7, 2022
- PeptiDream, Nihon Medi-Physics Wind Up Collab for Peptide-RI Conjugates
July 7, 2022
- France’s Pierre Fabre Gets Europe Rights to Urovant OAB Med Vibegron
July 7, 2022
- Kissei Kicks Off Japan PIII for Linzagolix in Uterine Fibroids
July 7, 2022
- Lecanemab Accepted for US Review, Action Date Set for January: Eisai/Biogen
July 7, 2022
- Opdivo Top-Selling Drug for 6 Months on End: Encise June Data
July 7, 2022
- Astellas CEO Sees Lower SGA and Trial Costs and Higher Research and Manufacturing Outlays Post-COVID
July 6, 2022
- Mitsubishi Tanabe Recalls Tranquilizer Depas over Contamination
July 6, 2022
- Kitasato Pharma to Be Dissolved at September-End: Meiji
July 6, 2022
- Astellas, Mogrify Ink Regenerative Medicine Collab for Sensorineural Hearing Loss
July 6, 2022
- Astellas Looks to Beat Innovation Malaise through Organizational and HR Rejig
July 6, 2022
- Shionogi Starts Document Submission for COVID Pill in China
July 5, 2022
- BMS Japan Launches New Head Office as It Looks to Spur Ideas through Casual Chats
July 5, 2022
- High Court Verdict for Bayer Employee Damage Suit Set for Sept. 7, Settlement Eyed Too
July 5, 2022
- Aculys, KNOCK ON THE DOOR Form Comprehensive Epilepsy Alliance
July 5, 2022
- Promotions via In-Hospital Seminars in HP Market Rise 28.4% YOY in May: Intage
July 5, 2022
- Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
July 4, 2022
- UCB Japan Snaps Up Zogenix Japan, Employees Too
July 4, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…